212 related articles for article (PubMed ID: 25772026)
1. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
Walter RB; Othus M; Paietta EM; Racevskis J; Fernandez HF; Lee JW; Sun Z; Tallman MS; Patel J; Gönen M; Abdel-Wahab O; Levine RL; Estey EH
Leukemia; 2015 Oct; 29(10):2104-7. PubMed ID: 25772026
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
Lima AS; de Mello MR; Fernandes E; Bezerra MF; Oliveira MM; Duarte BK; de Assis RA; Souto FR; Ramos CF; Machado CG; Pagnano K; Lucena-Araujo AR; Lorand-Metze I; Bezerra MA
Blood; 2015 Oct; 126(15):1863-5. PubMed ID: 26320101
[No Abstract] [Full Text] [Related]
3. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
4. Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Sproat L; Bolwell B; Rybicki L; Tench S; Chan J; Kalaycio M; Dean R; Sobecks R; Pohlman B; Andresen S; Sweetenham J; Copelan E
Leuk Lymphoma; 2010 Sep; 51(9):1699-704. PubMed ID: 20629524
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
6. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Ostronoff F; Othus M; Ho PA; Kutny M; Geraghty DE; Petersdorf SH; Godwin JE; Willman CL; Radich JP; Appelbaum FR; Stirewalt DL; Meshinchi S
Leukemia; 2013 Jan; 27(1):238-41. PubMed ID: 22722750
[No Abstract] [Full Text] [Related]
7. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
10. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
Godwin CD; Othus M; Powell MA; Buckley SA; Estey EH; Walter RB
Leuk Lymphoma; 2016 Oct; 57(10):2421-4. PubMed ID: 26754357
[No Abstract] [Full Text] [Related]
11. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
12. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
13. Questions regarding frontline therapy of acute myeloid leukemia.
Kantarjian H; O'Brien S
Cancer; 2010 Nov; 116(21):4896-901. PubMed ID: 20623787
[No Abstract] [Full Text] [Related]
14. Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Kurrle E; Ehninger G; Fackler-Schwalbe E; Freund M; Heil G; Hoelzer D; Link H; Löffler B; Lösch A; Mitrou PS
Haematol Blood Transfus; 1990; 33():254-60. PubMed ID: 2182418
[No Abstract] [Full Text] [Related]
15. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
16. Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Hiddemann W; Aul HC; Maschmeyer G; Urbanitz D; Lathan B; Reichle A; Köppler H; Donhuijsen-Ant R; Ludwig WD; Grüneisen T
Haematol Blood Transfus; 1990; 33():604-10. PubMed ID: 2182450
[No Abstract] [Full Text] [Related]
17. Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Grandits AM; Nguyen CH; Schlerka A; Hackl H; Sill H; Etzler J; Heyes E; Stoiber D; Grebien F; Heller G; Wieser R
Leukemia; 2021 Oct; 35(10):2827-2839. PubMed ID: 33782537
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
19. Therapy of acute myelogenous leukemia in adults.
Petti MC; Broccia G; Caronia F; Di Raimondo F; Fioritoni G; Ladogana S; Leone G; Liso V; Musso M; Neri A
Haematol Blood Transfus; 1990; 33():249-53. PubMed ID: 2182417
[No Abstract] [Full Text] [Related]
20. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
